Markets
Leerink Partners analyst Puneet Souda maintained a Buy rating on Castle Biosciences (CSTL – Research Report) on April 27. The company’s shares closed last Wednesday at $68.77.
According to TipRanks.com, Souda is a 5-star analyst with an average return of 27.0% and a 73.4% success rate. Souda covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, AbCellera Biologics, and Twist Bioscience.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $88.67 average price target, a 26.3% upside from current levels. In a report issued on April 27, Canaccord Genuity also maintained a Buy rating on the stock with a $94.00 price target.
Atricure (ATRC)
In a report issued on April 27, Danielle Antalffy from Leerink Partners maintained a Buy rating on Atricure, with a price target of $78.00. The company’s shares closed last Wednesday at $69.85, close to its 52-week high of $72.07.
According to TipRanks.com, Antalffy is a 5-star analyst with an average return of 25.9% and a 70.9% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Tandem Diabetes Care, and Edwards Lifesciences.
Atricure has an analyst consensus of Strong Buy, with a price target consensus of $75.57, representing a 15.3% upside. In a report issued on April 27, Oppenheimer also maintained a Buy rating on the stock with a $75.00 price target.
Illumina Vows to Fight Back as FTC Takes Aim at $8B Grail Acquisition genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Agilent Revs up Precision Medicine Push with Planned Resolution Bioscience Acquisition
March 3, 2021
[Source: Getty Images North America]
In a planned acquisition aimed at expanding its next-generation sequencing (NGS)-based capabilities in cancer diagnostics, Agilent Technologies announced yesterday it has agreed to buy Resolution Bioscience for up to $695 million.
Once rolled into the company, Resolution Bioscience’s liquid biopsy platform will complement Agilent’s existing tissue-based companion diagnostics business. In total, Agilent says the addressable market for these diagnostic tests is expected to be $3 billion by 2025, and double that by the end of the decade.
“By adding Resolution Bioscience’s liquid biopsy-based diagnostic technologies to our portfolio, we are strengthening Agilent’s offering to our biopharma customers and boosting the growth of our diagnostics and genomics business,” Agilent president and CEO Mike McMullen said in a statement.